OPKO Health (NASDAQ:OPK) Director Robert Scott Fishel bought 15,000 shares of the firm’s stock in a transaction dated Monday, April 16th. The shares were acquired at an average price of $3.01 per share, for a total transaction of $45,150.00. The purchase was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.
Robert Scott Fishel also recently made the following trade(s):
- On Friday, April 13th, Robert Scott Fishel bought 10,000 shares of OPKO Health stock. The shares were acquired at an average price of $3.02 per share, for a total transaction of $30,200.00.
Shares of OPK opened at $3.02 on Tuesday. The company has a current ratio of 1.14, a quick ratio of 0.98 and a debt-to-equity ratio of 0.02. OPKO Health has a 1 year low of $2.66 and a 1 year high of $7.90. The stock has a market cap of $1,672.83, a price-to-earnings ratio of -10.41 and a beta of 1.56.
Institutional investors and hedge funds have recently modified their holdings of the business. RK Asset Management LLC boosted its holdings in OPKO Health by 8.4% during the fourth quarter. RK Asset Management LLC now owns 932,752 shares of the biotechnology company’s stock worth $4,570,000 after buying an additional 72,209 shares during the last quarter. X Square Capital LLC bought a new position in OPKO Health during the fourth quarter worth about $2,363,000. Delek Group Ltd. bought a new position in OPKO Health during the fourth quarter worth about $382,000. Boulegeris Investments Inc. boosted its holdings in OPKO Health by 19.3% during the fourth quarter. Boulegeris Investments Inc. now owns 228,780 shares of the biotechnology company’s stock worth $1,121,000 after buying an additional 36,950 shares during the last quarter. Finally, Schwab Charles Investment Management Inc. boosted its holdings in OPKO Health by 43.0% during the third quarter. Schwab Charles Investment Management Inc. now owns 1,566,433 shares of the biotechnology company’s stock worth $10,746,000 after buying an additional 471,256 shares during the last quarter. Hedge funds and other institutional investors own 23.38% of the company’s stock.
Several equities analysts recently issued reports on the company. Zacks Investment Research cut OPKO Health from a “hold” rating to a “sell” rating in a report on Wednesday, March 7th. ValuEngine cut OPKO Health from a “sell” rating to a “strong sell” rating in a report on Thursday, March 1st. JPMorgan Chase cut OPKO Health from a “neutral” rating to an “underweight” rating and set a $7.00 price target on the stock. in a report on Friday, March 2nd. BidaskClub cut OPKO Health from a “sell” rating to a “strong sell” rating in a report on Wednesday, January 10th. Finally, Cantor Fitzgerald set a $20.00 price target on OPKO Health and gave the company a “buy” rating in a report on Thursday, March 1st. Four research analysts have rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the stock. OPKO Health presently has an average rating of “Hold” and a consensus target price of $11.29.
TRADEMARK VIOLATION NOTICE: This news story was published by Chaffey Breeze and is the property of of Chaffey Breeze. If you are reading this news story on another domain, it was copied illegally and republished in violation of US & international copyright and trademark legislation. The legal version of this news story can be accessed at https://www.chaffeybreeze.com/2018/04/17/opko-health-opk-director-purchases-45150-00-in-stock.html.
About OPKO Health
OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals business in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates Bio-Reference Laboratories, a clinical laboratory that offers laboratory testing services in the detection, diagnosis, evaluation, monitoring, and treatment of diseases.
Receive News & Ratings for OPKO Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OPKO Health and related companies with MarketBeat.com's FREE daily email newsletter.